Condition: Hepatocellular Carcinoma · Hepatocellular Cancer · Colorectal Cancer · Sponsor: National Cancer Centre, Singapore
This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with/without local ablation).
This description comes directly from the study's public registry record.
Si Lin Koo · +65 6436 8000 · koo.si.lin@singhealth.com.sg
Always discuss trial participation with your own doctor first.
| National Cancer Center Singapore | Singapore, Singapore | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04912765